These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 36794283)
21. Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial. Genovese MC; Kalunian K; Gottenberg JE; Mozaffarian N; Bartok B; Matzkies F; Gao J; Guo Y; Tasset C; Sundy JS; de Vlam K; Walker D; Takeuchi T JAMA; 2019 Jul; 322(4):315-325. PubMed ID: 31334793 [TBL] [Abstract][Full Text] [Related]
22. The Safety Profile of Upadacitinib in Patients with Rheumatoid Arthritis in Japan. Yamaoka K; Tanaka Y; Kameda H; Khan N; Sasaki N; Harigai M; Song Y; Zhang Y; Takeuchi T Drug Saf; 2021 Jun; 44(6):711-722. PubMed ID: 34041702 [TBL] [Abstract][Full Text] [Related]
23. A Matching-Adjusted Indirect Comparison of Upadacitinib Versus Tofacitinib in Adults with Moderate-to-Severe Rheumatoid Arthritis. Edwards CJ; Sawant R; Garg V; Du EX; Friedman A; Betts KA Rheumatol Ther; 2021 Mar; 8(1):167-181. PubMed ID: 33244703 [TBL] [Abstract][Full Text] [Related]
24. Upadacitinib improves patient-reported outcomes vs placebo or adalimumab in patients with rheumatoid arthritis: results from SELECT-COMPARE. Strand V; Tundia N; Bergman M; Ostor A; Durez P; Song IH; Enejosa J; Schlacher C; Song Y; Fleischmann R Rheumatology (Oxford); 2021 Dec; 60(12):5583-5594. PubMed ID: 33590829 [TBL] [Abstract][Full Text] [Related]
25. Disease activity measures at baseline predict structural damage progression: data from the randomized, controlled AMPLE and AVERT trials. Keystone EC; Ahmad HA; Yazici Y; Bergman MJ Rheumatology (Oxford); 2020 Aug; 59(8):2090-2098. PubMed ID: 31819995 [TBL] [Abstract][Full Text] [Related]
26. Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis. Rubbert-Roth A; Enejosa J; Pangan AL; Haraoui B; Rischmueller M; Khan N; Zhang Y; Martin N; Xavier RM N Engl J Med; 2020 Oct; 383(16):1511-1521. PubMed ID: 33053283 [TBL] [Abstract][Full Text] [Related]
27. Filgotinib in Rheumatoid Arthritis: A Profile of Its Use. Kim ES; Keam SJ Clin Drug Investig; 2021 Aug; 41(8):741-749. PubMed ID: 34304373 [TBL] [Abstract][Full Text] [Related]
28. Upadacitinib in patients from China, Brazil, and South Korea with rheumatoid arthritis and an inadequate response to conventional therapy. Zeng X; Zhao D; Radominski SC; Keiserman M; Lee CK; Meerwein S; Enejosa J; Sui Y; Mohamed MF; Park W Int J Rheum Dis; 2021 Dec; 24(12):1530-1539. PubMed ID: 34779576 [TBL] [Abstract][Full Text] [Related]
29. Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate-Naive Patients With Moderately-to-Severely Active Rheumatoid Arthritis (SELECT-EARLY): A Multicenter, Multi-Country, Randomized, Double-Blind, Active Comparator-Controlled Trial. van Vollenhoven R; Takeuchi T; Pangan AL; Friedman A; Mohamed MF; Chen S; Rischmueller M; Blanco R; Xavier RM; Strand V Arthritis Rheumatol; 2020 Oct; 72(10):1607-1620. PubMed ID: 32638504 [TBL] [Abstract][Full Text] [Related]
30. Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting. Alten R; Burkhardt H; Feist E; Krüger K; Rech J; Rubbert-Roth A; Voll RE; Elbez Y; Rauch C Arthritis Res Ther; 2018 Jan; 20(1):1. PubMed ID: 29329602 [TBL] [Abstract][Full Text] [Related]
31. Economic Benefit from Improvements in Quality of Life with Upadacitinib: Comparisons with Tofacitinib and Methotrexate in Patients with Rheumatoid Arthritis. Bergman M; Tundia N; Yang M; Orvis E; Clewell J; Bensimon A Adv Ther; 2021 Dec; 38(12):5649-5661. PubMed ID: 34636000 [TBL] [Abstract][Full Text] [Related]
33. Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response. Fleischmann RM; Genovese MC; Enejosa JV; Mysler E; Bessette L; Peterfy C; Durez P; Ostor A; Li Y; Song IH Ann Rheum Dis; 2019 Nov; 78(11):1454-1462. PubMed ID: 31362993 [TBL] [Abstract][Full Text] [Related]
34. Impact of Upadacitinib on Laboratory Parameters and Related Adverse Events in Patients with RA: Integrated Data Up to 6.5 Years. Charles-Schoeman C; Giles JT; Lane NE; Choy E; Furst DE; Vencovský J; Wilson AG; Burmester GR; Coombs D; Penn SK; Khan N; Yee JB; Rahawi K; McInnes IB Rheumatol Ther; 2024 Feb; 11(1):157-175. PubMed ID: 38180720 [TBL] [Abstract][Full Text] [Related]
35. Efficacy of etanercept in combination with methotrexate in moderate-to-severe rheumatoid arthritis is not dependent on methotrexate dosage. Gallo G; Brock F; Kerkmann U; Kola B; Huizinga TW RMD Open; 2016; 2(1):e000186. PubMed ID: 27175292 [TBL] [Abstract][Full Text] [Related]
36. Long-term Efficacy and Safety Following Switch Between Upadacitinib and Adalimumab in Patients with Rheumatoid Arthritis: 5-Year Data from SELECT-COMPARE. Fleischmann R; Blanco R; Van den Bosch F; Bessette L; Song Y; Penn SK; McDearmon-Blondell E; Khan N; Chan K; Mysler E Rheumatol Ther; 2024 Jun; 11(3):599-615. PubMed ID: 38498140 [TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studies. Genovese MC; Fleischmann R; Kivitz A; Lee EB; van Hoogstraten H; Kimura T; St John G; Mangan EK; Burmester GR Arthritis Res Ther; 2020 Jun; 22(1):139. PubMed ID: 32522251 [TBL] [Abstract][Full Text] [Related]
38. Rapid Onset of Efficacy of Baricitinib in Chinese Patients with Moderate to Severe Rheumatoid Arthritis: Results from Study RA-BALANCE. Li ZG; Hu JK; Li XP; Yang Y; Li XF; Xu JH; Zhang X; Xu J; Bao CD; He DY; Li ZJ; Wang GC; Zuo XX; Liu Y; Xiao ZY; Chen JW; Xin XF; Li JY; Jiang LD; Liu MR; Ji F; Li CG Adv Ther; 2021 Jan; 38(1):772-781. PubMed ID: 33237533 [TBL] [Abstract][Full Text] [Related]
39. Impact of flare on radiographic progression after etanercept continuation, tapering or withdrawal in patients with rheumatoid arthritis. Smolen JS; Pedersen R; Jones H; Mahgoub E; Marshall L Rheumatology (Oxford); 2020 Jan; 59(1):153-164. PubMed ID: 31257453 [TBL] [Abstract][Full Text] [Related]
40. The impact of filgotinib on patient-reported outcomes and health-related quality of life for patients with active rheumatoid arthritis: a post hoc analysis of Phase 3 studies. Bingham CO; Walker D; Nash P; Lee SJ; Ye L; Hu H; Khalid JM; Combe B Arthritis Res Ther; 2022 Jan; 24(1):11. PubMed ID: 34980223 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]